Pfizer Common Stock Total Equity vs Short Long Term Debt Total Analysis
PFE Stock | USD 25.40 0.14 0.55% |
Pfizer financial indicator trend analysis is much more than just breaking down Pfizer Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pfizer Inc is a good investment. Please check the relationship between Pfizer Common Stock Total Equity and its Short Long Term Debt Total accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
Common Stock Total Equity vs Short Long Term Debt Total
Common Stock Total Equity vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pfizer Inc Common Stock Total Equity account and Short Long Term Debt Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Pfizer's Common Stock Total Equity and Short Long Term Debt Total is 0.7. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Pfizer Inc, assuming nothing else is changed. The correlation between historical values of Pfizer's Common Stock Total Equity and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Pfizer Inc are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Common Stock Total Equity i.e., Pfizer's Common Stock Total Equity and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.7 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Short Long Term Debt Total
Most indicators from Pfizer's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. At present, Pfizer's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 240.8 B, whereas Tax Provision is projected to grow to (1.1 B).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 50.5B | 66.0B | 29.3B | 30.4B | Total Revenue | 81.3B | 100.3B | 58.5B | 39.5B |
Pfizer fundamental ratios Correlations
Click cells to compare fundamentals
Pfizer Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pfizer fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 167.5B | 154.2B | 181.5B | 197.2B | 226.5B | 237.8B | |
Short Long Term Debt Total | 52.1B | 38.3B | 37.0B | 34.9B | 75.0B | 78.8B | |
Total Current Liabilities | 37.3B | 25.9B | 42.7B | 42.1B | 47.8B | 50.2B | |
Total Stockholder Equity | 63.1B | 63.2B | 77.2B | 95.7B | 89.0B | 46.9B | |
Property Plant And Equipment Net | 14.0B | 13.9B | 14.9B | 16.3B | 18.9B | 11.3B | |
Net Debt | 50.8B | 36.5B | 35.1B | 34.5B | 72.2B | 75.8B | |
Retained Earnings | 97.7B | 96.8B | 103.4B | 125.7B | 118.4B | 124.3B | |
Cash | 1.3B | 1.8B | 1.9B | 416M | 2.9B | 2.0B | |
Non Current Assets Total | 134.7B | 119.2B | 121.8B | 145.9B | 183.2B | 192.3B | |
Non Currrent Assets Other | 4.5B | 4.6B | 7.7B | 13.2B | 9.1B | 5.3B | |
Cash And Short Term Investments | 9.8B | 12.2B | 31.1B | 22.7B | 12.7B | 14.9B | |
Net Receivables | 12.1B | 11.2B | 15.7B | 14.5B | 11.2B | 8.7B | |
Common Stock Shares Outstanding | 5.7B | 5.6B | 5.7B | 5.7B | 5.7B | 5.7B | |
Liabilities And Stockholders Equity | 167.5B | 154.2B | 181.5B | 197.2B | 226.5B | 237.8B | |
Non Current Liabilities Total | 66.7B | 64.8B | 61.3B | 59.2B | 89.4B | 93.9B | |
Inventory | 8.3B | 8.0B | 9.1B | 9.0B | 10.2B | 5.2B | |
Other Current Assets | 2.6B | 3.4B | 3.8B | 5.0B | 9.3B | 9.7B | |
Other Stockholder Equity | (23.4B) | (22.3B) | (20.8B) | (22.2B) | (21.9B) | (20.8B) | |
Total Liab | 104.0B | 90.8B | 104.0B | 101.3B | 137.2B | 144.1B | |
Property Plant And Equipment Gross | 14.0B | 28.4B | 30.0B | 31.4B | 35.0B | 36.7B | |
Total Current Assets | 32.8B | 35.1B | 59.7B | 51.3B | 43.3B | 32.2B | |
Short Term Debt | 16.2B | 2.7B | 2.2B | 2.9B | 10.9B | 5.7B | |
Intangible Assets | 35.4B | 28.5B | 25.1B | 43.4B | 64.9B | 68.1B | |
Property Plant Equipment | 14.0B | 13.9B | 14.9B | 16.3B | 18.9B | 11.3B | |
Accounts Payable | 4.2B | 4.3B | 5.6B | 6.8B | 6.7B | 7.0B | |
Accumulated Other Comprehensive Income | (11.6B) | (11.7B) | (5.9B) | (8.3B) | (8.0B) | (7.6B) | |
Common Stock Total Equity | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Short Term Investments | 8.5B | 10.4B | 29.1B | 22.3B | 9.8B | 9.3B | |
Capital Stock | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Common Stock | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Other Liab | 29.7B | 26.6B | 22.6B | 23.3B | 26.9B | 22.1B | |
Other Assets | 4.2B | 4.3B | 5.6B | 6.8B | 6.7B | 5.0B | |
Long Term Debt | 36.0B | 37.1B | 36.2B | 32.9B | 60.5B | 63.5B | |
Good Will | 58.7B | 49.6B | 49.2B | 51.4B | 67.8B | 40.7B | |
Treasury Stock | (110.8B) | (111.0B) | (111.4B) | (114.0B) | (114.5B) | (108.8B) | |
Current Deferred Revenue | 5.8B | 6.3B | 3.1B | 2.5B | 2.7B | 3.9B | |
Net Tangible Assets | (30.9B) | 63.2B | 77.2B | 95.7B | 89.0B | 93.5B |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.